Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
183 stopped studies mapped to Diffuse Large B-Cell Lymphoma and descendants · 88% state a reason
Over the 183 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05022797 | Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS | Phase 2 | terminated | Aug 26, 2021 | Fundacion CRIS de Investigación para Vencer el Cáncer | closed because of low recruitment | Enrollment / accrual |
| NCT04995536 | CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of… | Phase 1 | withdrawn | Aug 9, 2021 | City of Hope Medical Center | no accrual | Enrollment / accrual |
| NCT03103971 | huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell… | Phase 1 | terminated | Apr 7, 2017 | Fred Hutchinson Cancer Center | Terminated due to slow enrollment and end of funding | Enrollment / accrual |
| NCT03571828 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in… | Phase 1 | terminated | Jun 28, 2018 | Amgen | Amgen decided to discontinue study because of a business decision and not because of safety reasons | Safety / toxicity |
| NCT05611853 | Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell… | Phase 1 / Phase 2 | terminated | Nov 10, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT03684694 | Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell… | Phase 1 / Phase 2 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | Administrative decision | Other (stated, no rule matched) |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the… | Phase 2 | withdrawn | Jan 7, 2020 | M.D. Anderson Cancer Center | No Participants Enrolled | Enrollment / accrual |
| NCT03864419 | Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell… | Phase 1 | terminated | Mar 6, 2019 | Fred Hutchinson Cancer Center | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | Phase 1 | suspended | Apr 1, 2021 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | The trial was suspended due to the inability to enroll qualified participants | Enrollment / accrual |
| NCT05222438 | Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant | Phase 2 | withdrawn | Feb 3, 2022 | Barbara Ann Karmanos Cancer Institute | No accrual of participants in 18 months | Enrollment / accrual |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine… | Phase 1 / Phase 2 | terminated | Nov 7, 2016 | Philogen S.p.A. | Slow progression due to difficulties in finding eligible patients. Competitive clinical trials with… | Other (stated, no rule matched) |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant… | Phase 2 | terminated | Jan 8, 2010 | University of Nebraska | Study was closed to accrual for safety related to the frequency of BK infections. | Safety / toxicity |
| NCT02134782 | Yoga Fatigue Study | N/A | terminated | May 9, 2014 | The Hospital for Sick Children | The study was closed early for poor accrual when 125/210 planned participants had been enrolled and… | Enrollment / accrual |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | Phase 1 | terminated | Dec 3, 2021 | Exelixis | Due to Sponsor reasons. | Other (stated, no rule matched) |
| NCT05934097 | FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma | Phase 1 | withdrawn | Jul 6, 2023 | Fate Therapeutics | This study was withdrawn (Sponsor decision). | Sponsor / business decision |
| NCT04156828 | Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory… | Phase 1 | terminated | Nov 8, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients… | Early Phase 1 | terminated | Sep 5, 2017 | Rutgers, The State University of New Jersey | Lack of enrollment | Enrollment / accrual |
| NCT03850028 | Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution… | N/A | withdrawn | Feb 21, 2019 | University Medical Center Groningen | Closed prematurely because the accrual was not achieved | Enrollment / accrual |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT04236141 | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With… | Phase 3 | terminated | Jan 22, 2020 | Hoffmann-La Roche | Sponsor's decision, no safety concerns | Safety / toxicity |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT03123393 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Apr 21, 2017 | Calithera Biosciences, Inc | Lack of efficacy of the drug; no safety concern | Safety / toxicity |
| NCT03876028 | Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell… | Phase 1 | terminated | Mar 15, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT05228249 | Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for… | Phase 1 | withdrawn | Feb 8, 2022 | Fred Hutchinson Cancer Center | PI left institution and funding sponsor closed study. Study did not open to accrual, and no… | Investigator |
| NCT02531308 | Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)(DLBCL) | Phase 2 | terminated | Aug 24, 2015 | Rush University Medical Center | poor accrual | Enrollment / accrual |
| NCT02572453 | Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL | Phase 2 | terminated | Oct 9, 2015 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT02698189 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected… | Phase 1 | terminated | Mar 3, 2016 | Merck Sharp & Dohme LLC | This study was terminated due to limited efficacy and not due to safety reasons | Safety / toxicity |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell… | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03422523 | Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or…(ARGO) | Phase 2 | terminated | Feb 5, 2018 | University Hospital Southampton NHS Foundation Trust | Failure to reach pre-specified futility boundary | Efficacy / futility |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or…(MT-3724NHL001) | Phase 1 / Phase 2 | terminated | Feb 11, 2015 | Molecular Templates, Inc. | Sponsor decision following clinical hold | Sponsor / business decision |
| NCT03488251 | PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and… | Phase 2 | terminated | Apr 4, 2018 | Molecular Templates, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell… | Phase 1 / Phase 2 | suspended | Oct 15, 2018 | Northwestern University | Protocol being amended for stats/accrual changes as per PI | Enrollment / accrual |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without…(UNITY-NHL) | Phase 2 / Phase 3 | terminated | Jun 8, 2016 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT02374424 | Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients(GIOTTO) | Phase 2 | terminated | Feb 27, 2015 | Fondazione Italiana Linfomi - ETS | Interim analysis planned as per protocol didn't provide positive outcome therefore enrollment was… | Efficacy / futility |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT04535102 | POLA+BR for Relapsed or Refractory DLBCL | Phase 2 | withdrawn | Sep 1, 2020 | University of Colorado, Denver | Lack of sufficient patient population | Other (stated, no rule matched) |
| NCT04974996 | A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of…(LOTIS-8) | Phase 1 | withdrawn | Jul 23, 2021 | ADC Therapeutics S.A. | Decision to not proceed with study. | Other (stated, no rule matched) |
| NCT04456023 | Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse… | Phase 2 | withdrawn | Jul 2, 2020 | Novartis Pharmaceuticals | This study was cancelled before enrolling any patients for business related reasons. | Enrollment / accrual |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | Phase 1 | terminated | Nov 25, 2019 | The First Affiliated Hospital with Nanjing Medical University | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT01510184 | Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly… | Phase 3 | terminated | Jan 13, 2012 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen… | Phase 2 | terminated | May 17, 2019 | Jazz Pharmaceuticals | Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20… | Efficacy / futility |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic… | Phase 1 | terminated | Jan 9, 2019 | AbbVie | Safety | Safety / toxicity |
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse… | Phase 1 | terminated | Sep 26, 2018 | ADC Therapeutics S.A. | In a limited number of patients, no additional activity was evident for the combination vs.… | Other (stated, no rule matched) |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT01101581 | Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL | Phase 1 / Phase 2 | withdrawn | Apr 12, 2010 | Gilead Sciences | No subjects enrolled | Enrollment / accrual |
| NCT03873025 | A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse…(PLACARD) | Phase 1 / Phase 2 | withdrawn | Mar 13, 2019 | University College, London | There are insufficent funds to open the trial and start recruiting patients due to the impact of… | COVID-19 / pandemic |
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell… | Phase 2 | terminated | Sep 15, 2011 | Fred Hutchinson Cancer Center | Terminated due to insufficient funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 13, 2024source: clinicaltrials